Non-resective ablation therapy for hepatocellular carcinoma

Effectiveness measured by intention-to-treat and dropout from liver transplant waiting list

Robert A. Fisher, Daniel Maluf, A. H. Cotterell, T. Stravitz, L. Wolfe, V. Luketic, R. Sterling, M. Shiffman, M. Posner

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Background: Orthotopic liver transplantation (OLT) for patients with small hepatocellular carcinoma (HCC) is widely accepted, and the usefulness of local ablation techniques as a bridge for liver transplantation is still under investigation. Methods: From December 1997 to February 2003, patients with cirrhosis and T0-T1-T2-T3 stage HCC received multi-modality ablative therapy (MMT) for the treatment of their HCC and were evaluated for OLT; listed, and transplanted when an allograft became available. MMT included radiofrequency ablation (RFA), and/or Trans-Arterial Chemo-Embolization (TACE), and alcohol (EtOH) ablation, followed by Trans-Arterial Chemo-Infusion (TACI), with repeated treatments based on follow up hepatic magnetic resonance imaging (MRI) during the waiting period for OLT. Results: A total of 135 HCC patients were seen at our center within this time frame. The intention-to-treat group included 33 (24.4%) patients with T0, T1, T2, T3 HCC and cirrhosis. There were 31 men and two women. The mean age was 53.6 ± 7.2 yr. All patients received MMT with a mean of 2.90 ± 1.5 procedures per patient. Tumor-node-metastasis (TNM) stages at time of listing were: T0 in one patient, T1 in nine patients, T2 in 17 patients, and T3 in six patients. Twenty-eight (85%) patients have received OLT. Five (12.19%) patients were listed and removed (dropout) from the transplant waiting list after waiting 5, 5, 5, 8, and 14 months respectively. The waiting time of the HCC listed group was 9.1 ± 14.8 months with a mean follow up of 32 months. OLT patient survival and cancer-free survival are 92.9% and 95.24%, respectively; the overall survival of intention-to-treat group was 79% at 32 months follow up. Predictors of dropout included an α-fetoprotein (AFP, > 400 ng/mL) and T3 HCC stage. Conclusion: Aggressive ablation therapy with a short transplant waiting time optimizes the use of OLT for curative intent in selective cirrhotic HCC patients.

Original languageEnglish (US)
Pages (from-to)502-512
Number of pages11
JournalClinical Transplantation
Volume18
Issue number5
DOIs
StatePublished - Oct 1 2004

Fingerprint

Waiting Lists
Hepatocellular Carcinoma
Transplants
Liver
Liver Transplantation
Therapeutics
Survival
Fibrosis
Ablation Techniques
Fetal Proteins
Allografts
Neoplasms

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Non-resective ablation therapy for hepatocellular carcinoma : Effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. / Fisher, Robert A.; Maluf, Daniel; Cotterell, A. H.; Stravitz, T.; Wolfe, L.; Luketic, V.; Sterling, R.; Shiffman, M.; Posner, M.

In: Clinical Transplantation, Vol. 18, No. 5, 01.10.2004, p. 502-512.

Research output: Contribution to journalArticle

Fisher, Robert A. ; Maluf, Daniel ; Cotterell, A. H. ; Stravitz, T. ; Wolfe, L. ; Luketic, V. ; Sterling, R. ; Shiffman, M. ; Posner, M. / Non-resective ablation therapy for hepatocellular carcinoma : Effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. In: Clinical Transplantation. 2004 ; Vol. 18, No. 5. pp. 502-512.
@article{4f1dd86a169c49359b2b8235c29f18fc,
title = "Non-resective ablation therapy for hepatocellular carcinoma: Effectiveness measured by intention-to-treat and dropout from liver transplant waiting list",
abstract = "Background: Orthotopic liver transplantation (OLT) for patients with small hepatocellular carcinoma (HCC) is widely accepted, and the usefulness of local ablation techniques as a bridge for liver transplantation is still under investigation. Methods: From December 1997 to February 2003, patients with cirrhosis and T0-T1-T2-T3 stage HCC received multi-modality ablative therapy (MMT) for the treatment of their HCC and were evaluated for OLT; listed, and transplanted when an allograft became available. MMT included radiofrequency ablation (RFA), and/or Trans-Arterial Chemo-Embolization (TACE), and alcohol (EtOH) ablation, followed by Trans-Arterial Chemo-Infusion (TACI), with repeated treatments based on follow up hepatic magnetic resonance imaging (MRI) during the waiting period for OLT. Results: A total of 135 HCC patients were seen at our center within this time frame. The intention-to-treat group included 33 (24.4{\%}) patients with T0, T1, T2, T3 HCC and cirrhosis. There were 31 men and two women. The mean age was 53.6 ± 7.2 yr. All patients received MMT with a mean of 2.90 ± 1.5 procedures per patient. Tumor-node-metastasis (TNM) stages at time of listing were: T0 in one patient, T1 in nine patients, T2 in 17 patients, and T3 in six patients. Twenty-eight (85{\%}) patients have received OLT. Five (12.19{\%}) patients were listed and removed (dropout) from the transplant waiting list after waiting 5, 5, 5, 8, and 14 months respectively. The waiting time of the HCC listed group was 9.1 ± 14.8 months with a mean follow up of 32 months. OLT patient survival and cancer-free survival are 92.9{\%} and 95.24{\%}, respectively; the overall survival of intention-to-treat group was 79{\%} at 32 months follow up. Predictors of dropout included an α-fetoprotein (AFP, > 400 ng/mL) and T3 HCC stage. Conclusion: Aggressive ablation therapy with a short transplant waiting time optimizes the use of OLT for curative intent in selective cirrhotic HCC patients.",
author = "Fisher, {Robert A.} and Daniel Maluf and Cotterell, {A. H.} and T. Stravitz and L. Wolfe and V. Luketic and R. Sterling and M. Shiffman and M. Posner",
year = "2004",
month = "10",
day = "1",
doi = "10.1111/j.1399-0012.2004.00196.x",
language = "English (US)",
volume = "18",
pages = "502--512",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Non-resective ablation therapy for hepatocellular carcinoma

T2 - Effectiveness measured by intention-to-treat and dropout from liver transplant waiting list

AU - Fisher, Robert A.

AU - Maluf, Daniel

AU - Cotterell, A. H.

AU - Stravitz, T.

AU - Wolfe, L.

AU - Luketic, V.

AU - Sterling, R.

AU - Shiffman, M.

AU - Posner, M.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Background: Orthotopic liver transplantation (OLT) for patients with small hepatocellular carcinoma (HCC) is widely accepted, and the usefulness of local ablation techniques as a bridge for liver transplantation is still under investigation. Methods: From December 1997 to February 2003, patients with cirrhosis and T0-T1-T2-T3 stage HCC received multi-modality ablative therapy (MMT) for the treatment of their HCC and were evaluated for OLT; listed, and transplanted when an allograft became available. MMT included radiofrequency ablation (RFA), and/or Trans-Arterial Chemo-Embolization (TACE), and alcohol (EtOH) ablation, followed by Trans-Arterial Chemo-Infusion (TACI), with repeated treatments based on follow up hepatic magnetic resonance imaging (MRI) during the waiting period for OLT. Results: A total of 135 HCC patients were seen at our center within this time frame. The intention-to-treat group included 33 (24.4%) patients with T0, T1, T2, T3 HCC and cirrhosis. There were 31 men and two women. The mean age was 53.6 ± 7.2 yr. All patients received MMT with a mean of 2.90 ± 1.5 procedures per patient. Tumor-node-metastasis (TNM) stages at time of listing were: T0 in one patient, T1 in nine patients, T2 in 17 patients, and T3 in six patients. Twenty-eight (85%) patients have received OLT. Five (12.19%) patients were listed and removed (dropout) from the transplant waiting list after waiting 5, 5, 5, 8, and 14 months respectively. The waiting time of the HCC listed group was 9.1 ± 14.8 months with a mean follow up of 32 months. OLT patient survival and cancer-free survival are 92.9% and 95.24%, respectively; the overall survival of intention-to-treat group was 79% at 32 months follow up. Predictors of dropout included an α-fetoprotein (AFP, > 400 ng/mL) and T3 HCC stage. Conclusion: Aggressive ablation therapy with a short transplant waiting time optimizes the use of OLT for curative intent in selective cirrhotic HCC patients.

AB - Background: Orthotopic liver transplantation (OLT) for patients with small hepatocellular carcinoma (HCC) is widely accepted, and the usefulness of local ablation techniques as a bridge for liver transplantation is still under investigation. Methods: From December 1997 to February 2003, patients with cirrhosis and T0-T1-T2-T3 stage HCC received multi-modality ablative therapy (MMT) for the treatment of their HCC and were evaluated for OLT; listed, and transplanted when an allograft became available. MMT included radiofrequency ablation (RFA), and/or Trans-Arterial Chemo-Embolization (TACE), and alcohol (EtOH) ablation, followed by Trans-Arterial Chemo-Infusion (TACI), with repeated treatments based on follow up hepatic magnetic resonance imaging (MRI) during the waiting period for OLT. Results: A total of 135 HCC patients were seen at our center within this time frame. The intention-to-treat group included 33 (24.4%) patients with T0, T1, T2, T3 HCC and cirrhosis. There were 31 men and two women. The mean age was 53.6 ± 7.2 yr. All patients received MMT with a mean of 2.90 ± 1.5 procedures per patient. Tumor-node-metastasis (TNM) stages at time of listing were: T0 in one patient, T1 in nine patients, T2 in 17 patients, and T3 in six patients. Twenty-eight (85%) patients have received OLT. Five (12.19%) patients were listed and removed (dropout) from the transplant waiting list after waiting 5, 5, 5, 8, and 14 months respectively. The waiting time of the HCC listed group was 9.1 ± 14.8 months with a mean follow up of 32 months. OLT patient survival and cancer-free survival are 92.9% and 95.24%, respectively; the overall survival of intention-to-treat group was 79% at 32 months follow up. Predictors of dropout included an α-fetoprotein (AFP, > 400 ng/mL) and T3 HCC stage. Conclusion: Aggressive ablation therapy with a short transplant waiting time optimizes the use of OLT for curative intent in selective cirrhotic HCC patients.

UR - http://www.scopus.com/inward/record.url?scp=4644336438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644336438&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2004.00196.x

DO - 10.1111/j.1399-0012.2004.00196.x

M3 - Article

VL - 18

SP - 502

EP - 512

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 5

ER -